Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Bone Marrow Transplantation

• Publication date

  2014-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/bmt.2013.107PMID 23892326
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease

  2015cited by this paper
• Allogeneic hematopoietic stem cell donation—standardized assessment of donor outcome data: A consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT)

  2013cited by this paper
• Low incidences of acute and chronic graft-versus-host disease after unrelated bone marrow transplantation with low-dose anti-T lymphocyte globulin

  2012cited by this paper
• First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.

  2012cited by this paper
• Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation

  2012cited by this paper
• Secondary treatment of acute graft-versus-host disease: a critical review.

  2012cited by this paper
• European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3—2009 Update

  2011cited by this paper
• Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease.

  2011cited by this paper
• Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation.

  2011cited by this paper
• Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009

  2010cited by this paper
• Comparison between horse and rabbit antithymocyte globulin as first-line treatment for patients with severe aplastic anemia: a single-center retrospective study

  2010cited by this paper
• Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD.

  2010cited by this paper
• Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.

  2009cited by this paper
• Defining the intensity of conditioning regimens: working definitions.

  2009cited by this paper
• Viral disease prevention after hematopoietic cell transplantation

  2009cited by this paper
• Folinic acid administration following MTX as prophylaxis for GVHD

  2009cited by this paper
• Haematopoietic stem cell donor registries: World Marrow Donor Association recommendations for evaluation of donor health

  2008cited by this paper
• Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond

  2007cited by this paper
• The type of ATG matters -- natural killer cells are influenced differentially by Thymoglobulin, Lymphoglobulin and ATG-Fresenius.

  2007cited by this paper
• Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin.

  2006cited by this paper
• Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia.

  2006cited by this paper
• Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation.

  2006cited by this paper
• National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

  2005cited by this paper
• Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT

  2005cited by this paper
• National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.

  2005cited by this paper
• Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissio

  2003cited by this paper
• Nonmyeloablative preparative regimens: how relevant for acute myelogenous leukemia?

  2001cited by this paper
• Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation.

  1998cited by this paper
• A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow Transplantation (EBMT)

  1997cited by this paper
• Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia.

  1991cited by this paper
• Bone Marrow Transplant

  1990cited by this paper
• Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

  1988cited by this paper
• Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

  1988cited by this paper
• Graft rejection following HLA matched T‐lymphocyte depleted bone marrow transplantation

  1986cited by this paper
• Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia.

  1986cited by this paper
• Differential effects of horse ATG and rabbit ATG on T cell and T cell subset levels measured by monoclonal antibodies.

  1984cited by this paper
• Methotrexate and citrovorum factor after histoincompatible allogeneic bone marrow transplants in dogs.

  1978cited by this paper
• Bone marrow transplantation.

  1977cited by this paper

• Effect of Conversion From Intravenous to Oral Administration on Cyclosporine Exposure in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation.

  2026cites this paper
• Evaluation of cyclophosphamide for steroid-refractory hepatic acute graft-vs-host disease after allogeneic hematopoietic stem cell transplantation

  2026cites this paper
• Reduced morbidity and mortality of cGVHD in patients who received treatment with mesenchymal stromal cells for steroid-resistant aGVHD: long-term follow-up of a randomized phase 3 trial

  2025cites this paper
• Mycophenolate mofetil‐induced colitis versus colonic graft‐versus‐host disease: a comparative histologic study with artificial intelligence model development

  2025cites this paper
• Efficacy and safety of ruxolitinib combined with steroids for first-line treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation: a single-center, real-world experience

  2025cites this paper
• Trends in GVHD Epidemiology, Prophylaxis and Management: The Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO) GVHD24 Study

  2025cites this paper
• Treatment of IL-10RA deficiency of pediatric patients with very early onset inflammatory bowel disease by allogeneic haematopoietic stem cell transplantation

  2025cites this paper
• Ruxolitinib treatment outcomes in acute graft-versus-host disease (aGvHD) in a real-world setting in Finland

  2025cites this paper
• Histopathologic evaluation of gastrointestinal graft-versus-host disease: Opportunities for improvement based on a survey of practicing pathologists.

  2025cites this paper
• International consensus on the diagnosis and management of endocrine complications of β and α thalassemia in children and adolescents.

  2025cites this paper
• Patterns of Graft-Versus-Host Disease (GvHD) Prevention Practices in the Eastern Mediterranean (EM) Region: A Worldwide Network for Blood & Marrow Transplantation (WBMT) Global Study.

  2025cites this paper
• Mesenchymal stem cells in treating human diseases: molecular mechanisms and clinical studies

  2025cites this paper
• Mesenchymal stem cells added to second-line therapy improve response and failure-free survival in steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: A meta-analysis of randomized controlled trials

  2025cites this paper
• The Safety and Efficacy of Ruxolitinib in an Infant With Familial Hemophagocytic Syndrome Type 3: A Bridging Therapy Toward Hematopoietic Cell Transplantation and Treatment of Post‐Transplant Complications, Including Sinusoidal Obstruction Syndrome

  2025cites this paper
• Acute and chronic graft-versus-host disease treatment and management in the Eastern Mediterranean region: A Worldwide Network for Blood and Marrow Transplantation survey.

  2025cites this paper
• Changes in Chronic Graft-versus-Host Disease Treatment over Time: A 15-Years Survey within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland.

  2025cites this paper
• Evaluating Axatilimab as a treatment option for chronic graft-versus-host disease.

  2025cites this paper
• Utilization of Clinical Data and Evaluation of Biomarkers in the Investigation of Graft-Versus-Host Disease Outcomes.

  2025cites this paper
• Immunological mechanisms underlying the novel application of mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) in graft-versus-host disease (GvHD) therapy

  2025cites this paper
• REAL-WORLD OUTCOMES OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE TREATED WITH RUXOLITINIB

  2025cites this paper
• Optimal GVHD Prophylaxis.

  2025cites this paper
• Chronic Graft-versus-Host disease trends over 30 years - a study by the EBMT transplant complications working party

  2025cites this paper
• Outcomes in Critically Ill Allogeneic Hematopoietic Stem-Cell Transplantation Recipients.

  2024cites this paper
• TMX1, a disulfide oxidoreductase, is necessary for T cell function through regulation of CD3ζ

  2024cites this paper
• 人类疱疹病毒感染在造血干细胞移植后难治性肠道移植物抗宿主病中的作用及诊断和治疗

  2024cites this paper
• The Long-Acting Glucagon-Like Peptide-2 Analog Apraglutide Enhances Intestinal Protection and Survival After Chemotherapy and Allogeneic Transplantation in Mice

  2024cites this paper
• Impact of cytopenias and early versus late treatment with ruxolitinib in patients with steroid-refractory acute or chronic graft-versus-host disease

  2024cites this paper
• Combined Cytokine Blockade Therapy (CCBT) Using Basiliximab and Infliximab for Treatment of Steroid-Refractory Graft-Versus-Host Disease (SR-GvHD)

  2024cites this paper
• Ruxolitinib for the treatment of acute graft-versus-host disease: a retrospective analysis

  2024cites this paper
• Acute graft versus host disease 1976–2020: reduced incidence and predictive factors

  2024cites this paper
• Mismatched unrelated donors allogeneic hematopoietic stem cell transplantation with antithymocyte globulin for hematological malignancies: a multicenter retrospective study in China

  2024cites this paper
• Early Access for Medicines in ITALY: The Case of Ruxolitinib for Patients with Graft-Versus-Host Disease

  2024cites this paper
• Efficacy and safety of human umbilical cord-derived mesenchymal stem cells versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease: a multicentre, randomized, double-blind, phase 2 trial

  2024cites this paper
• Cost-Effectiveness of Extracorporeal Photopheresis in Patients With Chronic Graft-vs-Host Disease

  2024cites this paper
• Immunological and homeostatic pathways of alpha -1 antitrypsin: a new therapeutic potential

  2024cites this paper
• What should be the optimal dose of post-transplantation cyclophosphamide for GVHD prophylaxis in allogeneic stem cell transplantation?

  2024cites this paper
• Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children: a systematic review and individual patient data meta-analysis

  2024cites this paper
• Fecal microbiota transplantation in capsules for the treatment of steroid refractory and steroid dependent acute graft vs. host disease: a pilot study

  2024cites this paper
• 巴利昔单抗短期替代钙调蛋白抑制剂预防急性移植物抗宿主病的探索性研究

  2024cites this paper
• Post‐transplant‐cyclophosphamide and short‐term Everolimus as graft‐versus‐host‐prophylaxis in patients with relapsed/refractory lymphoma and myeloma—Final results of the phase II OCTET‐EVER trial

  2024cites this paper
• Post-transplant-cyclophosphamide plus everolimus as GvHD prophylaxis in refractory T- and B-cell lymphoma

  2024cites this paper
• Ruxolitinib in patients with graft versus host disease (GvHD): findings from a compassionate use program

  2024cites this paper
• Human leukocyte antigen 7/8-matched unrelated bone marrow transplantation using anti-thymocyte globulin in children

  2023cites this paper
• Real-world clinical characterization, healthcare resource utilization and productivity loss in chronic graft versus host patients exposed to extracorporeal photopheresis in Sweden.

  2023cites this paper
• Pathophysiology of gastrointestinal acute graft‐versus‐host disease and the potential role of glucagon‐like peptide 2

  2023cites this paper
• Challenges and concepts in the diagnosis and management of ocular graft-versus-host disease

  2023cites this paper
• Mafosfamide, a cyclophosphamide analog, causes a proinflammatory response and increased permeability on endothelial cells in vitro

  2023cites this paper
• Risk factors for early onset acute kidney injury after allogeneic haematopoietic stem cell transplantation and the role of drug–drug interactions

  2023cites this paper
• Graft failure in allogeneic hematopoietic stem cell recipients: diagnosis and treatment

  2023cites this paper
• Acute Graft-versus-Host Disease: An Update on New Treatment Options

  2023cites this paper
• Graft conditioning with fluticasone propionate reduces graft‐versus‐host disease upon allogeneic hematopoietic cell transplantation in mice

  2023cites this paper
• Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study

  2023cites this paper
• Novel therapies for graft versus host disease with a focus on cell therapies

  2023cites this paper
• Machine learning applications and challenges in graft-versus-host disease: a scoping review

  2023cites this paper
• Post-transplantation Cyclophosphamide-based Graft-versus-host-disease Prophylaxis Compared to Methotrexate-cyclosporine a in Matched-related Allogeneic Hematopoietic Stem Cell Transplantation.

  2023cites this paper
• Intrabone transplant of a single unwashed umbilical cord blood unit with ATG-free and sirolimus-based GvHD prophylaxis: fast immune-reconstitution and long-term disease control in 30 patients with high-risk diseases.

  2023cites this paper
• Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation

  2023cites this paper
• Immunosuppressant adherence in adult outpatient hematopoietic cell transplant recipients

  2023cites this paper
• Gastrointestinal Biopsies in the Patient Post-Stem Cell Transplant: An Approach to Diagnosis.

  2023cites this paper
• Monitoring of strength, inflammation and muscle function in allogenic stem-cell transplantation patients – a pilot study for novel biomarker and risk stratification determination

  2023cites this paper
• CD3+TCRαβ/CD19+ depleted mismatched family or unrelated donor salvage stem cell transplantation for graft dysfunction in inborn errors of immunity.

  2023cites this paper
• The role of JAK inhibitors in hematopoietic cell transplantation

  2022cites this paper
• The Role of Fecal Microbiota Transplantation in the Treatment of Acute Graft-versus-Host Disease

  2022cites this paper
• Low dose Unfractionated Heparin Prophylaxis is a Safe Strategy for the Prevention of Hepatic Sinusoidal Obstruction Syndrome After Myeloablative Adult Allogenic Stem Cell Transplant

  2022cites this paper
• Steroid-Refractory Gut Graft-Versus-Host Disease: What We Have Learned From Basic Immunology and Experimental Mouse Model

  2022cites this paper
• Is It Possible to Separate the Graft-Versus-Leukemia (GVL) Effect Against B Cell Acute Lymphoblastic Leukemia From Graft-Versus-Host Disease (GVHD) After Hematopoietic Cell Transplant?

  2022cites this paper
• Lower levels of cyclosporine between days 0 and +21 may reduce later relapses without increasing graft‐versus‐host disease in children and adolescents with acute lymphoblastic leukemia who undergo myeloablative TBI‐based allogeneic hematopoietic cell transplantation

  2022cites this paper
• 维多珠单抗治疗糖皮质激素耐药急性肠道移植物抗宿主病2例报告并文献复习

  2022cites this paper
• Mocravimod, a selective S1PR modulator in allogeneic hematopoietic stem cell transplantation for malignancy.

  2022cites this paper
• Posttransplant cyclophosphamide‐based anti–graft‐vs‐host disease prophylaxis in patients with acute lymphoblastic leukemia treated in complete remission with allogeneic hematopoietic cell transplantation from human leukocyte antigen‐mismatched unrelated donors versus haploidentical donors: A study o

  2022cites this paper
• Human leukocyte antigen evolutionary divergence influences outcomes of paediatric patients and young adults affected by malignant disorders given allogeneic haematopoietic stem cell transplantation from unrelated donors

  2022cites this paper
• Current Prophylaxis and Treatment Approaches for Acute Graft-Versus-Host Disease in Haematopoietic Stem Cell Transplantation for Children With Acute Lymphoblastic Leukaemia

  2022cites this paper
• Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation

  2022cites this paper
• Endocrine Sequelae in 157 Pediatric Survivors of Hematopoietic Stem Cell Transplantation (HSCT)

  2022cites this paper
• Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience

  2022cites this paper
• Implementation of Routine Endoscopy with Narrow Band Imaging in the Evaluation of Oral and Upper Airways Lesions in Oral Chronic Graft-Versus-Host Disease: A Preliminary Study

  2022cites this paper
• Insights into mechanisms of graft-versus-host disease through humanised mouse models

  2022cites this paper
• First-line steroid-free systemic treatment of acute and chronic graft-versus-host disease after novel prophylaxis regimens

  2022cites this paper
• The soluble VCAM-1 level is a potential biomarker predicting severe acute graft versus host disease after allogeneic hematopoietic cell transplantation

  2022cites this paper
• Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tract

  2022cites this paper
• Structure-Activity relationship of 1-(Furan-2ylmethyl)Pyrrolidine-Based Stimulation-2 (ST2) inhibitors for treating graft versus host disease.

  2022cites this paper
• HSCT with Mismatched Unrelated Donors (MMUD): A Comparison of Different Platforms for GvHD Prophylaxis

  2022cites this paper
• Post-transplant cyclophosphamide for GVHD prophylaxis in pediatrics with chronic active Epstein-Barr virus infection after haplo-HSCT

  2022cites this paper
• Oncologic emergencies and urgencies: A comprehensive review

  2022cites this paper
• Lymph Node Fibroblastic Reticular Cells Attenuate Immune Responses Through Induction of Tolerogenic Macrophages at Early Stage of Transplantation

  2022cites this paper
• Established and Emerging Treatments of Skin GvHD

  2022cites this paper
• Bloodstream infections' origins following fecal microbiota transplantation: a strain-level analysis

  2021cites this paper
• Beyond steroids: A systematic review and proposed solutions to managing acute graft-versus-host disease in adolescents and young adults.

  2021cites this paper
• Immune Suppression in Allogeneic Hematopoietic Stem Cell Transplantation.

  2021cites this paper
• Origins of bloodstream infections following fecal microbiota transplantation: a strain-level analysis

  2021cites this paper
• Toxic epidermal necrolysis‐like acute cutaneous graft‐versus‐host disease in a stem cell recipient – a diagnostic dilemma

  2021cites this paper
• Safety of FLT3 inhibitors in patients with acute myeloid leukemia

  2021cites this paper
• Targeting ITK signaling for T cell-mediated diseases

  2021cites this paper
• Immune Reconstitution-Based Score for Risk Stratification of Chronic Graft-Versus-Host Disease Patients

  2021cites this paper
• Outcome of allogeneic hematopoietic stem cell transplant recipients admitted to the intensive care unit with a focus on haploidentical graft and sequential conditioning regimen: results of a retrospective study

  2021cites this paper
• Leucovorin Rescue After Methotrexate Graft-Versus-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment, and Hospital Length of Stay.

  2021cites this paper
• Graft-Versus-Host Disease (GvHD) Prophylaxis

  2021cites this paper
• The Role of Myeloid-Derived Suppressor Cells (MDSCs) in Graft-versus-Host Disease (GVHD)

  2021cites this paper
• Economic burden of acute steroid-refractory graft-versus-host disease in commercially insured pediatric patients

  2021cites this paper
• Acute Graft-Versus-Host Disease, Prophylaxis and Therapy

  2021cites this paper